{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:29:51Z","timestamp":1780410591154,"version":"3.54.1"},"reference-count":130,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beem.2010.11.002","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T16:27:00Z","timestamp":1308500820000},"page":"443-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Insulin resistance in treated HIV infection"],"prefix":"10.1016","volume":"25","author":[{"given":"E.R.","family":"Feeney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.beem.2010.11.002_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1017\/S000711450000088X","article-title":"Obesity, insulin resistance and diabetes\u2013a worldwide epidemic","volume":"83","author":"Seidell","year":"2000","journal-title":"The British Journal of Nutrition"},{"key":"10.1016\/j.beem.2010.11.002_bib2","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","article-title":"Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy","volume":"14","author":"Tebas","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3282ef1bb4","article-title":"Chronic kidney disease in HIV infection: an urban epidemic","volume":"21","author":"Wyatt","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002030-200101260-00008","article-title":"Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy","volume":"15","author":"Suarez","year":"2001","journal-title":"AIDS"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2010.11.002_bib6","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/00126334-200306012-00003","article-title":"AIDS and older Americans at the end of the twentieth century","volume":"33","author":"Mack","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib7","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2010.11.002_bib8","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1055\/s-2001-18576","article-title":"Insulin resistance: definition and consequences","volume":"109","author":"Lebovitz","year":"2001","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"10.1016\/j.beem.2010.11.002_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/diacare.14.3.173","article-title":"Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease","volume":"14","author":"DeFronzo","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.11.002_bib11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2337\/diacare.25.8.1371","article-title":"Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers","volume":"25","author":"Marques-Vidal","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/diab.45.6.742","article-title":"Increased insulin resistance and insulin secretion in nondiabetic African\u2013Americans and Hispanics compared with non-Hispanic whites. The insulin resistance atherosclerosis study","volume":"45","author":"Haffner","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2010.11.002_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/oby.2010.59","article-title":"Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study","author":"Preis","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.beem.2010.11.002_bib14","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.beem.2010.11.002_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2010.11.002_bib16","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib18","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2337\/diabetes.54.7.1914","article-title":"Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model","volume":"54","author":"Chen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2010.11.002_bib19","first-page":"L10","article-title":"Use of oral glucose tolerance testing to estimate insulin sensitivity in patients with HIV infection","volume":"10","author":"Mulligan","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.11.002_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0168-8227(99)00116-3","article-title":"Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures","volume":"47","author":"Gutt","year":"2000","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.beem.2010.11.002_bib21","author":"WHO"},{"key":"10.1016\/j.beem.2010.11.002_bib22","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.285.16.2109","article-title":"Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study","volume":"285","author":"de Vegt","year":"2001","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.11.002_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2796.2004.01336.x","article-title":"High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius","volume":"256","author":"Soderberg","year":"2004","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/diacare.23.2.187","article-title":"Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population","volume":"23","author":"Rohlfing","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib25","doi-asserted-by":"crossref","unstructured":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:p.1327\u201334.","DOI":"10.2337\/dc09-9033"},{"key":"10.1016\/j.beem.2010.11.002_bib26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1089\/aid.2006.22.1242","article-title":"Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients","volume":"22","author":"Diop","year":"2006","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.beem.2010.11.002_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0140-6736(92)92814-V","article-title":"Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study","volume":"340","author":"Martin","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.11.002_bib28","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1056\/NEJM199312303292703","article-title":"Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians","volume":"329","author":"Lillioja","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.ATV.20.2.538","article-title":"Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki policemen study","volume":"20","author":"Pyorala","year":"2000","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.beem.2010.11.002_bib30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1464-5491.2002.00719.x","article-title":"Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death","volume":"19","author":"Hedblad","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0021-9150(03)00198-9","article-title":"Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus","volume":"169","author":"Matsumoto","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2010.11.002_bib32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/diacare.25.7.1135","article-title":"HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona diabetes complications study","volume":"25","author":"Bonora","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2010.11.002_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/meta.2002.32804","article-title":"Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes","volume":"51","author":"Temelkova-Kurktschiev","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib35","author":"European AIDS Clinical Society"},{"key":"10.1016\/j.beem.2010.11.002_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","article-title":"Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease","volume":"135","author":"Murphy","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society \u2013 USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.11.002_bib38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/pgmj.72.848.365","article-title":"Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy","volume":"72","author":"Jain","year":"1996","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/j.beem.2010.11.002_bib39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0026-0495(91)90059-6","article-title":"Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men","volume":"40","author":"Hommes","year":"1991","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib40","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","article-title":"Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients","volume":"12","author":"Walli","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib42","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study","volume":"16","author":"Noor","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib43","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/00002030-200105040-00001","article-title":"Metabolic effects of indinavir in healthy HIV-seronegative men","volume":"15","author":"Noor","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib44","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/QAD.0b013e32826fbc54","article-title":"Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers","volume":"21","author":"Lee","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e3181e6a7d9","article-title":"Boosting dose Ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers","author":"Taylor","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib46","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200411050-00005","article-title":"The effects of HIV protease inhibitors atazanavir and lopinavir\/ritonavir on insulin sensitivity in HIV-seronegative healthy adults","volume":"18","author":"Noor","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/590154","article-title":"No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir\u2013ritonavir in healthy subjects without HIV infection: a placebo-controlled trial","volume":"47","author":"Dube","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.11.002_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effects of lopinavir\/ritonavir in HIV-negative men","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/QAI.0b013e3181c190f4","article-title":"Insulin sensitivity in multiple pathways is differently affected during zidovudine\/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy","volume":"53","author":"van Vonderen","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1468-1293.2008.00690.x","article-title":"Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers","volume":"10","author":"Tomaka","year":"2009","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib52","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e328315a7a5","article-title":"Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults","volume":"22","author":"Carr","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib53","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults","volume":"292","author":"Fleischman","year":"2007","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib54","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32833562c5","article-title":"Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacl.2008.08.442","article-title":"Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG study A5152s stein: lipoprotein changes on antiretroviral therapy","volume":"2","author":"Stein","year":"2008","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.beem.2010.11.002_bib56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00126334-200106010-00006","article-title":"Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients","volume":"27","author":"Dube","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib58","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib59","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.qai.0000176654.97392.c7","article-title":"Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal","volume":"40","author":"Yan","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbalip.2009.09.018","article-title":"Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment","volume":"1801","author":"Villarroya","year":"2010","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.beem.2010.11.002_bib61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.qai.0000147527.64863.1a","article-title":"Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia","volume":"38","author":"Mallon","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e31814b94e2","article-title":"Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study","volume":"46","author":"Grunfeld","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00002030-200204120-00005","article-title":"Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations","volume":"16","author":"Murata","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.beem.2010.11.002_bib66","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib67","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0140-6736(91)91294-5","article-title":"Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy","volume":"337","author":"Arnaudo","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.11.002_bib68","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D: A:D) study","volume":"31","author":"De Wit","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2010.11.002_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1468-1293.2007.00537.x","article-title":"Lipodystrophy and weight changes: data from the Swiss HIV Cohort study, 2000\u20132006","volume":"9","author":"Nguyen","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0b013e31819c16f4","article-title":"Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study","volume":"51","author":"Mercier","year":"2009","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/QAI.0b013e318158c0a6","article-title":"Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy","volume":"46","author":"Mutimura","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib72","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib73","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2010.11.002_bib74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00126334-200308150-00005","article-title":"The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons","volume":"33","author":"Mehta","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3851\/IMP1298","article-title":"Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 study","volume":"14","author":"Cacoub","year":"2009","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.11.002_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e3181e5b1f0","article-title":"Insulin Resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus","author":"Ryan","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib77","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.beem.2010.11.002_bib78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel","volume":"31","author":"Schambelan","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib79","author":"European AIDS Clinical Society"},{"key":"10.1016\/j.beem.2010.11.002_bib80","article-title":"Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients","author":"Gianotti","year":"2010","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2008.10.032","article-title":"Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV\/HCV co-infected patients","volume":"50","author":"Merchante","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.beem.2010.11.002_bib82","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2893.2008.01021.x","article-title":"Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus","volume":"15","author":"Castaneda-Sceppa","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.beem.2010.11.002_bib83","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib84","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0002-9149(92)90981-4","article-title":"Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors","volume":"69","author":"Barnard","year":"1992","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.beem.2010.11.002_bib85","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1210\/jc.2007-2733","article-title":"The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy","volume":"93","author":"Lindegaard","year":"2008","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib86","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.metabol.2006.05.018","article-title":"Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women","volume":"55","author":"Engelson","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy","volume":"8","author":"Madruga","year":"2007","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.beem.2010.11.002_bib88","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib89","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/jac\/dkp100","article-title":"Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen","volume":"63","author":"Gerschenson","year":"2009","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.beem.2010.11.002_bib90","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","article-title":"Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine","volume":"19","author":"McComsey","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1592\/phco.28.3.323","article-title":"Lipid-lowering efficacy and safety after switching to atazanavir\u2013ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus","volume":"28","author":"Nguyen","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beem.2010.11.002_bib93","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2310\/JIM.0b013e3181641b26","article-title":"Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir\/ritonavir","volume":"56","author":"Busti","year":"2008","journal-title":"Journal of Investigative Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib94","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/QAD.0b013e32832ba904","article-title":"Effects of switching from lopinavir\/ritonavir to atazanavir\/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients","volume":"23","author":"Stanley","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib95","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-06-0648","article-title":"Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects","volume":"156","author":"Guffanti","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2010.11.002_bib96","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir\u2013ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.beem.2010.11.002_bib97","author":"Aberg","year":"2010","journal-title":"METABOLIK (Metabolic Evaluation in Treatment-na\u00efves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir over 12 weeks"},{"key":"10.1016\/j.beem.2010.11.002_bib98","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/340863","article-title":"Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy","volume":"35","author":"Estrada","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.11.002_bib100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2362.2004.01379.x","article-title":"Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors","volume":"34","author":"Petit","year":"2004","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.beem.2010.11.002_bib101","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"Fisac","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib102","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib103","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1210\/jc.2002-020709","article-title":"Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance","volume":"87","author":"Hadigan","year":"2002","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib104","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial","volume":"143","author":"van Wijk","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib106","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.11.002_bib107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1086\/375850","article-title":"A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy","volume":"37","author":"Worth","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.11.002_bib108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(00)80306-8","article-title":"Cross-regulation of C\/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity","volume":"3","author":"Wu","year":"1999","journal-title":"Molecular Cell"},{"key":"10.1016\/j.beem.2010.11.002_bib109","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.11.002_bib110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"Gelato","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.002_bib111","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib112","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)","volume":"13","author":"Slama","year":"2008","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.11.002_bib113","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/QAD.0b013e328339e274","article-title":"Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy \u2013 a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.11.002_bib115","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/518005","article-title":"A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy","volume":"195","author":"Cavalcanti","year":"2007","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.beem.2010.11.002_bib116","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib117","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/593179","article-title":"Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction","volume":"198","author":"Mallon","year":"2008","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.beem.2010.11.002_bib118","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.11.002_bib119","doi-asserted-by":"crossref","first-page":"c4848","DOI":"10.1136\/bmj.c4848","article-title":"Rosiglitazone: what went wrong?","volume":"341","author":"Cohen","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2010.11.002_bib120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.300.5.509","article-title":"Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial","volume":"300","author":"Lo","year":"2008","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.11.002_bib121","author":"Falutz","year":"2010","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib122","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/db05-1646","article-title":"Effects of recombinant human IGF-I\/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes","volume":"55","author":"Saukkonen","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2010.11.002_bib123","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2009-2502","article-title":"Effects of insulin-like growth factor (IGF)-I\/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance","author":"Rao","year":"2010","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib124","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.11.002_bib125","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1463-1326.2007.00832.x","article-title":"Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels","volume":"10","author":"Li","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib126","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1592\/phco.27.10.1449","article-title":"Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection","volume":"27","author":"Sheffield","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beem.2010.11.002_bib127","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1463-1326.2009.01187.x","article-title":"Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes","volume":"12","author":"Aschner","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.beem.2010.11.002_bib128","series-title":"GS-9350: a pharmaco-enhancer without anti-hiv activity","author":"Mathias","year":"2009"},{"key":"10.1016\/j.beem.2010.11.002_bib129","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/QAD.0b013e3283372d76","article-title":"Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience","volume":"24","author":"Nozza","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.002_bib130","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml","author":"Arribas","year":"2009","journal-title":"AIDS"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:44:10Z","timestamp":1761497050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X10001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521690X10001727"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2010.11.002","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin resistance in treated HIV infection","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2010.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}